Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial...

Area of Science:

• Cardiovascular Physiology
• Ischemia-Reperfusion Injury
• Endothelial Function

Background:

• Acute ischemic preconditioning (IPC) is known to protect against ischemia-reperfusion (IR) injury.
• The efficacy of repeated IPC exposure in providing sustained protection has not been thoroughly investigated.
• Understanding the role of cyclooxygenase-2 (COX-2) in repeated IPC responses is crucial.

Purpose of the Study:

• To evaluate whether daily IPC episodes provide continued protection against IR injury in a human forearm model.
• To investigate the involvement of cyclooxygenase-2 in the protective mechanisms of repeated IPC.

Main Methods:

• A crossover design involving 30 healthy volunteers randomized into three protocols: IR alone, 1-day IPC, and 7-day IPC.
• Flow-mediated dilation (FMD) was measured pre- and post-IR to assess endothelial function.
• Subjects received either a cyclooxygenase-2 inhibitor (celecoxib) or placebo for 7 days during each protocol.

Main Results:

• IR alone significantly reduced FMD, indicating endothelial dysfunction.
• Both 1-day and 7-day IPC protocols completely prevented the IR-induced reduction in FMD.
• Celecoxib administration did not affect the protective responses to IR or IPC, suggesting a COX-2 independent mechanism.

Conclusions:

• Daily episodes of IPC provide sustained protection against IR-induced endothelial dysfunction in humans.
• The protective mechanism of repeated IPC appears to be independent of cyclooxygenase-2 activity.
• Repeated IPC demonstrates potential as a therapeutic strategy for mitigating IR injury.